parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocyte progenitor cells (1527 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 136	0.79
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7236

receipt 7245: SCD5 in dopamine neurons, braak

power: full sample -0.11 (p 0.664, n 18), 95% CI -0.55 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.794, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.867, n 18). could be the mix.
skeptic: leave-one-out range -0.25 to +0.00, sign flips 1; without severely affected donors -0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCD5 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7244: SCD5 in oligodendrocytes, braak

power: full sample -0.19 (p 0.455, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.16 (p 0.532, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.05 (p 0.840, n 18). could be the mix.
skeptic: leave-one-out range -0.34 to -0.12, sign flips 0; without severely affected donors -0.19 (p 0.455, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCD5 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts